TABLE 1

Studies Included in the Systematic Review

	Clinical indication		Time from therapy completion to PET (mo)		Follow-up (mo)		No. of patients	No. of female patients	Age (y)		Exclusion of patients with PIF or PD during treatment
Study	Clinical indication	Study design	Median	Range	Median	Range	No. of patients	No. of female patients	Median	Range	Exclusion of patients with PIF or PD during treatment
HD and NHL
de Wit et al. (25)	Residual mass	Retrospective	2	<10	13	1–26	34	NR	43	21–73	NR
Foo et al. (26)	Posttherapy	Retrospective	NR	NR	NR or 13^*	3–65	24^†	33%^‡	33^‡	20–67	NR
Jerusalem et al. (27)	Posttherapy	Prospective	NR	1–3	23 or 21^*	NR	54	27 (50%)	47	15–80	Yes
Mikosch et al. (28)	Posttherapy^§^‖	Retrospective	NR	>1	NR	>12	93	NR	NR	NR	NR
Mikhaeel et al. (29)	Residual mass	Retrospective	NR	<1	38	16–68	32	31 (31%)	NR	NR	NR
Schaefer et al. (30)	Posttherapy^¶	Retrospective	3	NR	9.3^#	NR	41^†	38%^‡	39.6^#	NR	NR
HD
Filmont et al. (16)	Posttherapy	Retrospective	5.2	1–87	14	6–39	32	22 (53%)	30	6–65	NR
Friedberg et al. (17)	Posttherapy	Prospective	NR	<1	24	10–32	32^†	36%^‡	30^‡	18–60	NR
Guay et al. (18)	Posttherapy	Retrospective	2	0–55	15	1–60	48	25 (50%)	38	17–78	NR
Jerusalem et al. (31)	Posttherapy^§	Prospective	1	NR	NR^§	NR	36	23 (64%)^‡	28	13–71	Yes
Keresztes et al. (32)	Residual mass^‖	Retrospective	3^#	2–5	50 or 62^**	5–98	31^†	42%^‡	31 or 37^**	13–70	NR
Mocikova et al. (33)	Posttherapy^‖	Retrospective	NR	NR	25	NR	94	44 (47%)^‡	30	28–85	NR
Rigacci et al. (19)	Posttherapy	Prospective	4	2–8	45	NR	28	14 (50%)	30.6	16–73	NR
Spaepen et al. (20)	Posttherapy	Retrospective	NR	1–3	30	12–48	60	33 (45%)	35	11–75	NR
Weihrauch et al. (34)	Residual mass^§	Prospective	NR	<4	28	16–68	28	8 (26%)	36	18–76	NR
Wickmann et al. (21)	Posttherapy	Retrospective	NR	0–7	32	1–56	48	36	NR	<18	NR
NHL
Juweid et al. (22)	Posttherapy	Retrospective	1	0–5	35	25–60	54	NR	58	21–79	No
Mikhaeel et al. (23)	Posttherapy	Retrospective	NR	<2	30	7–56	45^†	37%^‡	NR	NR	Yes
Spaepen et al. (24)	Posttherapy	Retrospective	NR	1–3	21	11–50	93	34 (37%)	47	2–77	NR

↵* Patients without or with residual mass, respectively.
↵† Only subset of participants who were evaluated with PET after completion of therapy.
↵‡ Data abstracted from total participants, not limited to patients who were evaluated with PET at end of therapy.
↵§ Some PET scans were taken at the end of salvage therapy.
↵‖ Some participants underwent PET multiple times.
↵¶ Each lymphoma lesion was evaluated as the unit of analysis.
↵# Mean.
↵** Patients with or without bulky mass before therapy, respectively.
NR = not reported; PD = progressive disease; PIF = primary induction failure.